Kiniksa Pharmaceuticals, Ltd. (KNSA) Misses Q3 EPS by 19c

Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) reported Q3 EPS of ($0.18), $0.19 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $112.21 million versus the consensus estimate of $110.29 million.

For earnings history and earnings-related data on Kiniksa Pharmaceuticals, Ltd. (KNSA) click here.

You May Also Be Interested In

• PG&E Corp, Edison Spike; California Assembly Won't Take Vote On Utility Wildfire Bill
• Interactive Brokers (IBKR) call put ratio 1 call 1.2 puts as share price down 6.2%
• LP Building Solutions to halt OSB output at Texas plant in October